Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial
Authors
- Jay Yang (ORCID: https://orcid.org/0009-0002-4332-1384)
- Shaheen Tomah (ORCID: https://orcid.org/0000-0003-3864-7494)
- Sarah Browne
- Julio Gutiérrez (ORCID: https://orcid.org/0000-0002-2212-064X)
- John J. Suschak (ORCID: https://orcid.org/0000-0002-2867-8265)
- Bertrand Georges
- M. Scott Harris (ORCID: https://orcid.org/0000-0001-5141-5773)
- M. Scot Roberts
Institutions
- Altimmune (United States) (US)
- Scripps Clinic (US)